. 2017 May 18;6(5):e005795. doi: 10.1161/JAHA.117.005795

Table 4.

Risk of Nonfatal Ischemic Stroke Associated With the Use of CaM and the Effect of Dose and Duration of Treatment

	Cases (%) n=2690	Controls (%) n=19 538	Nonadjusted OR^a (95% CI)	Adjusted OR^b (95% CI)
CaM
Nonuse	2578 (95.84)	18 769 (96.06)	1 (ref)	1 (ref)
Current	50 (1.86)	293 (1.50)	1.25 (0.92–1.69)	1.18 (0.86–1.61)
Recent	32 (1.19)	214 (1.10)	1.09 (0.75–1.59)	1.04 (0.71–1.53)
Past	30 (1.12)	262 (1.34)	0.83 (0.56–1.21)	0.79 (0.54–1.17)
Calcium dose^c
<1000 mg/d	17 (0.63)	155 (0.79)	0.80 (0.48–1.32)	0.76 (0.45–1.26)
≥1000 mg/d	21 (0.78)	67 (0.34)	2.29 (1.40–3.75)	2.09 (1.25–3.49)
Unknown	12 (0.45)	71 (0.36)	1.23 (0.67–2.27)	1.22 (0.65–2.29)
Duration^c
≤180 d	24 (0.89)	134 (0.69)	1.31 (0.85–2.03)	1.23 (0.79–1.93)
>180 d	26 (0.97)	159 (0.81)	1.19 (0.78–1.81)	1.13 (0.74–1.73)

CaM indicates calcium supplements as monotherapy; CI, confidence interval; OR, odds ratio.

Adjusted only for matching factors (age, sex, and calendar year).

Adjusted for matching factors and for the variables described in Methods and Table 1.

Among current users compared with nonusers.